News

Brief news reports on Tuberculosis

Fake medicine common in many sub-Saharan African countries

Read More →

WHO and PATH publish toolkit on strategies to address MDR-TB

WHO and PATH have published a toolkit designed to help countries develop or strengthen the multidrug-resistant tuberculosis (MDR-TB) components within national TB strategies or plans.

Read More →

Tuberculosis bacterium's outer cell wall disarms the body's defense to remain infectious

COLUMBUS, Ohio -- The bacterium that causes tuberculosis has a unique molecule on its outer cell surface that blocks a key part of the body's defense. New research suggests this represents a novel mechanism in the microbe's evolving efforts to remain hidden from the human immune system.

Read More →

Smoking set to cause 40 million extra tuberculosis deaths

If worldwide smoking trends continue to 2050, tuberculosis (TB) mortality rates could jump by 40 million, according to a study published online today in the British Medical Journal.

Read More →

Nepali scholar makes breakthrough in TB

Gyanu Lamichhane, a 35-year-old Nepali researcher at John Hopkins University School of Medicine, has drawn the world several steps closer in finding a better, faster and reliable cure for tuberculosis (TB), which kills over two million people across the globe each year.

Read More →

WHO framework targets tuberculosis—diabetes link

Read More →

United Arab Emirates introduces mandatory HIV, TB tests for migrant workers

Read More →

Once-daily nevirapine inferior to efavirenz in HIV/TB-coinfected patients

Recent studies have unequivocally demonstrated that patients with HIV/tuberculosis (TB) coinfection should begin antiretroviral therapy (ART) as soon as possible, but no later than 8 weeks, after initiation of TB therapy. The WHO recommends that ART for coinfected patients consist of two nucleosides (AZT or tenofovir + either 3TC or FTC) + efavirenz — and considers nevirapine an acceptable option when efavirenz cannot be used. Currently, nevirapine is the more widely used third drug because it is less expensive.

Read More →

Time to increase efforts against HIV/AIDS, TB

In a Huffington Post opinion piece, Kolleen Bouchane, director of ACTION, asks whether President Barack Obama will "heed Archbishop [Desmond] Tutu's call to action" in a recent Washington Post opinion piece "and do his part to end AIDS." She says, "While campaigning, President Obama promised to expand PEPFAR 'by $1 billion a year in new money over the next five years' and provide $50 billion by 2013 to fight HIV/AIDS worldwide. We are not on track to see even those promises become reality. We are not on track for the leadership to change the course of HIV and AIDS that Tutu has called for."

Read More →

Drug-evading tuberculosis shows rising superbug threat in China

Almost half of tuberculosis patients with a strain resistant to two or more drugs hadn’t had the disease before, according to a study at a Chinese hospital.

Read More →

Page 503 of 514 · Total posts: 10

←First 502 503 504 Last→